Compare CXW & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXW | ZLAB |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2001 | 2017 |
| Metric | CXW | ZLAB |
|---|---|---|
| Price | $30.78 | $17.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $32.00 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.3M | 968.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.19 | 38.46 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $2,211,182,000.00 | $460,156,000.00 |
| Revenue This Year | $17.13 | $9.75 |
| Revenue Next Year | $5.64 | $26.03 |
| P/E Ratio | $77.32 | ★ N/A |
| Revenue Growth | 12.72 | ★ 15.33 |
| 52 Week Low | $15.74 | $15.96 |
| 52 Week High | $30.77 | $41.20 |
| Indicator | CXW | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 84.86 | 45.85 |
| Support Level | $18.38 | $16.78 |
| Resistance Level | N/A | $19.41 |
| Average True Range (ATR) | 1.24 | 0.68 |
| MACD | 0.28 | 0.21 |
| Stochastic Oscillator | 97.36 | 55.79 |
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.